Polymer-lipid hybrid nanoparticles conjugated with anti-egf receptor antibody for targeted drug delivery to hepatocellular carcinoma

Nanomedicine

Volumn 9, Issue 2, 2014, Pages 279-293

  Gao, Jie ^a,b   Xia, Yu ^a   Chen, Huaiwen ^a   Yu, Yongsheng ^a   Song, Jinjing ^a   Li, Wei ^a,b   Qian, Weizhu ^a,b   Wang, Hao ^a,b   Dai, Jianxin ^a,b   Guo, Yajun ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b National Engineering Research Center for Antibody Medicine   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Adriamycin; Antibody; EGFR; Hepatocellular carcinoma; Nanoparticle

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; LIPID; NANOPARTICLE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL VIABILITY; CELLS; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; ENDOCYTOSIS; FLUORESCENCE SPECTROSCOPY; GENE OVEREXPRESSION; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIGHT SCATTERING; LIPID MONOLAYER; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PRIORITY JOURNAL; SIDE POPULATION CELL; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANTIBODIES; CARCINOMA, HEPATOCELLULAR; DRUG DELIVERY SYSTEMS; LIPIDS; LIVER NEOPLASMS; MICROSCOPY, CONFOCAL; NANOPARTICLES; POLYMERS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84896700482     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.20     Document Type: Article

References (31)

1. Michielsen PP, Francque SM, Van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J. Surg. Oncol. 5(20), 23-27 (2005).
2. Yin C, Lin Y, Zhang X et al. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology 48(5), 1528-1539 (2008).
3. Carr BI. Hepatocellular carcinoma: Current management and future trends. Gastroenterology 127(5), 218-224 (2004).
4. Pazo Cid RA, Lao J, Lanzuela M. Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma. JAMA 304(19), 781 (2011).
5. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: Pathophysiology and prevention. FASEB J. 11(12), 931-936 (1997).
6. Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer 5(3), 161-167 (2005).
7. Farokhzad OC, Langer R. Nanomedicine: Developing smarter therapeutic and diagn ostic modalities. Adv. Drug Deliv. Rev. 58(14), 1456-1459 (2006).
8. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science 303(5665), 1818-1822 (2004).
9. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnology 2(12), 751-760 (2007).
10. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4(2), 145-160 (2005).
11. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6(9), 688-701 (2006).
12. Liu Y, Li K, Pan J, Liu B, Feng SS. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of docetaxel. Biomaterials 31(2), 330-338 (2010).
13. Tong R, Cheng JJ. Anticancer polymeric nanomedicines. Polym. Rev. 47(3), 3450-3481 (2007).
14. Li Y, Pei Y, Zhang X et al. PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats. J. Control. Release 71(2), 203-211 (2011).
15. Chan JM, Zhang L, Yuet KP et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 30(8), 1627-1634 (2009).
16. Liu Y, Pan J, Feng SS. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: Effects of surfactants on particles size, characteristics and in vitro performance. Int. J. Pharm. 395(1-2), 243-250 (2011).
17. Gao J, Feng SS, Guo Y. Antibody engineering promotes nanomedicine for cancer treatment. Nanomedicine (Lond.) 5(8), 1141-1145 (2011).
18. Hu CM, Kaushal S, Tran Cao HS et al. Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol. Pharm. 7(3), 914-920 (2010).
19. Xu XR, Huang J, Xu ZG et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc. Natl Acad. Sci. USA 98(26), 15089-15098 (2001).
20. Giannelli G, Sgarra C, Porcelli L, Azzariti A, Antonaci S, Paradiso A. EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Lett. 262(2), 257-264 (2008).
21. Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epito pes. Clin. Cancer Res. 10(7), 2530-2537 (2004).
22. Liu P, Li Z, Zhu Met al. Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma. J. Mater. Sci. Mater. Med. 21(2), 551-556 (2011).
23. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resist. Upd at. 14(3), 150-163 (2011).
24. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5(4), 275-284 (2005).
25. Galindo-Rodriguez S, All? mann E, Fessi H, Doelker E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm. Res. 21(8), 1428-1439 (2004).
26. Miller CA. Self-emulsification of surfactant-oil mixtures produced by diffusion and chemical reaction. J. Cosmet. Sci. 52(2), 144-145 (2001).
27. Gao J, Kou G, Wang H et al. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity. Breast Cancer Res. Treat. 115(1), 29-41 (2009).
28. Chiba T, Kita K, Zheng YW et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44(1), 240-251 (2006).
29. Harris MA, Yang H, Low BE et al. Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res. 68(24), 10051-10059 (2008).
30. Visvader JE, Lindema n GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev. Cancer 8(10), 755-768 (2008).
31. Tewes F, Munnier E, Antoon B, et al. Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur. J. Pharm. Biopharm. 66(3), 488-492 (2007).